Combination Therapies in BRAF-Positive NSCLC

, , ,

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss their insights on current and emerging combination strategies in the treatment of BRAF-positive NSCLC, focusing on the integration of targeted therapies, immunotherapies, or both.

  1. Dr Gadgeel: What are your thoughts on the current and emerging combination strategies in BRAF- positive NSCLC treatment, particularly those involving targeted therapies, immunotherapies, or both? (Planchard D, et al. NPJ Precis Oncol. 2024)

Related Content:

Leveraging ctDNA Platforms in High-Risk Patients: Current Applications and Future Potential
Translating Metastatic Insights to Early-Stage Management: Current Practices and Future Direction
EGFR Therapy Evolution: Resistance Mechanisms, Combination Strategies, and Advanced Testing